PBM Reform Impact on Future Market Landscape and Access

Our client needed an assessment of how converging PBM reforms at the federal and state levels—together with indirect pressures from transparency rules, cash-pay channels, and antitrust scrutiny of vertical integration—would reshape PBM business models, payer and employer incentives, and market behavior. Leadership also wanted to understand where Big 3 PBM revenue may migrate across the enterprise as vertically integrated entities work to replace lost rebate income. The client’s executive team requested the assessment to inform contracting, formulary strategy, pricing dynamics, evidence demands, and BD priorities.

We began by mapping the current PBM landscape—reform provisions and timelines, adjacent pressures, and how PBMs are already adapting operations and compensation across incumbents, traditional players, and disruptors. We then mined investor and financial intelligence (earnings transcripts, investor presentations, and SEC filings) to quantify, where feasible, current and projected revenue across the Big 3’s key profit centers: specialty pharmacy dispensing, GPO fees, rebate retention, mail order, biosimilar white-label, 340B, pharmacy steering, and clinical programs. From there, we assessed the diversification strategies these entities may pursue to offset lost rebate revenue. Finally, we translated PBM evolution into its downstream impact on contracting, formulary strategy, evidence demands, and pricing, along with adjacent channel effects across 340B, specialty pharmacy, copay assistance, and the medical benefit.

We provided senior leadership with a set of scenarios to shape their expectations for how market behavior may evolve under mounting policy pressure—and what it means for their portfolio, pipeline, BD priorities, and PBM-engagement strategy over the next two to three years.